Sugi Predict

Sugi Predict / Targets / UGT1A1

UGT1A1

UDP-glucuronosyltransferase 1A1 · P22309 · UGT1A1 on Sugi Atlas →

31,313 patent compounds predicted against UGT1A1, 24,122 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6837 SCHEMBL6837 0.62 4/20
SCHEMBL6164 SCHEMBL6164 0.54 4/20
SCHEMBL6185 SCHEMBL6185 0.54 4/20
SCHEMBL6550 SCHEMBL6550 0.54 4/20
SCHEMBL6186 SCHEMBL6186 0.52 4/20
SCHEMBL6229 SCHEMBL6229 0.51 4/20
Atazanavir Atazanavir (SCHEMBL41696) 1.00 3/20
Atazanavir Atazanavir (SCHEMBL41697) 1.00 3/20
Atazanavir Atazanavir (SCHEMBL291519) 0.94 3/20
Atazanavir Atazanavir (SCHEMBL341700) 0.94 3/20
Atazanavir Atazanavir (SCHEMBL52068) 0.91 3/20
SCHEMBL6253 SCHEMBL6253 0.91 3/20
SCHEMBL6570 SCHEMBL6570 0.91 3/20
SCHEMBL5845 SCHEMBL5845 0.90 3/20
SCHEMBL6785 SCHEMBL6785 0.81 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL6668) 0.80 3/20
SCHEMBL6266 SCHEMBL6266 0.77 3/20
SCHEMBL11372 SCHEMBL11372 0.77 3/20
SCHEMBL6179 SCHEMBL6179 0.77 3/20
SCHEMBL6302 SCHEMBL6302 0.73 3/20

Clinical trials — most relevant to UGT1A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cholestatic Drug-induced Liver Injury PHASE4UNKNOWN
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy PHASE4COMPLETED
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial PHASE3UNKNOWN
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer PHASE2COMPLETED
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer PHASE2COMPLETED
CBD for Pain Following Orthopedic Shoulder Surgery PHASE1/PHASE2RECRUITING
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma PHASE1/PHASE2RECRUITING
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma PHASE1/PHASE2RECRUITING
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer PHASE2COMPLETED
Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer PHASE2COMPLETED
Study of FID-022 in Participants With Advanced Solid Tumors PHASE1RECRUITING
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours PHASE1UNKNOWN
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin PHASE1COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors PHASE1UNKNOWN
OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma PHASE1COMPLETED
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer PHASE1COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine PHASE1COMPLETED
Irinotecan in Treating Asian Patients With Solid Tumors PHASE1COMPLETED
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors PHASE1COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors PHASE1COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac EARLY_PHASE1RECRUITING
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C nanCOMPLETED
Escalated Dose of Irinotecan in mCRC nanCOMPLETED
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care nanRECRUITING
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy nanRECRUITING
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy nanCOMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline nanCOMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype nanUNKNOWN
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UGT1A1 binder may also engage these)

ProteinNameSimilarity
UGT1A4 UDP-glucuronosyltransferase 1A4 0.998 landscape →
Q64550 — 0.998 Q64550 →
UGT1A3 UDP-glucuronosyltransferase 1A3 0.998 landscape →
P35504 — 0.997 P35504 →
Q64638 — 0.996 Q64638 →
Q64637 — 0.996 Q64637 →
Q63886 — 0.995 Q63886 →
Q28612 — 0.994 Q28612 →
P20720 — 0.992 P20720 →
P08430 — 0.989 P08430 →
P70691 — 0.989 P70691 →
Q64435 — 0.989 Q64435 →
Q6ZQM8 — 0.988 Q6ZQM8 →
UGT1A6 UDP-glucuronosyltransferase 1A6 0.988 landscape →
Q64633 — 0.987 Q64633 →
Q64634 — 0.986 Q64634 →
Q62452 — 0.985 Q62452 →
Q28611 — 0.979 Q28611 →
UGT1A10 UDP-glucuronosyltransferase 1A10 0.958 landscape →
UGT1A8 UDP-glucuronosyltransferase 1A8 0.957 landscape →
P36510 — 0.955 P36510 →
P36512 — 0.952 P36512 →
UGT1A9 UDP-glucuronosyltransferase 1A9 0.952 landscape →
Q80X89 — 0.950 Q80X89 →
O02663 — 0.950 O02663 →
Q6PDD0 — 0.950 Q6PDD0 →
P54855 — 0.950 P54855 →
Q9R110 — 0.948 Q9R110 →
P0DTE5 — 0.948 P0DTE5 →
Q8BWQ1 — 0.947 Q8BWQ1 →